Unfortunately the very existence of this presentation suggests Kilian and the board are thinking about raising funds again.
Lining up trial outcomes (real ones - not sites opened) against cash spend seems to be the sound thing to do analytically.
Looking at Kilian's history (past) of delivery against his chances of future performance seems prudent analytically too.
What has Kilian done since replacing Ross?
Add to My Watchlist
What is My Watchlist?